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ORIGINAL ARTICLE

Design and Characterization of Melt-In-Mouth
Tablets of Montelukast Sodium and Levocetirizine
Dihydrochloride
Nagesh C*, Sunil Attimarad, Chandrashekhara S, Suma Naduvinamani, Mahendra Dalhmia
Maratha Mandal’s College of Pharmacy, Belgaum, Karnataka, India.

ABSTRACT
The main aim of this investigation was to develop mouth dissolving tablets of montelukast sodium and levocetirizine
dihydrochloride using different super disintegrants with an intention to achieve better drug bio-availability and patient’s
compliance. Montelukast sodium is an anti-asthmatic agent and levocetirizine dihydrochloride is an anti-allergic agent.
This combination is most commonly used to treat asthmatic conditions and allergic rhinitis. Mouth dissolving tablet
of montelukast sodium and levocetirizine dihydrochloride was prepared by using directly compressible diluents and
different types of disintegrating agents like croscarmellose sodium, crospovidone, sodium starch glycolate and Kyron
T314. The formulations were tested for derived properties of powders, uniformity of weight, thickness, strength,
percentage friability, percentage content uniformity, wetting time, water absorption capacity, disintegration time and
in-vitro dissolution studies. The results of all parameters were within the satisfactory range. From the results it was
also found that formulation F4 with 8% w/w crospovidone was coined as the best formulation, which showed least
wetting and disintegration time and high drug release (96.060.80%± of montelukast sodium and 91.691.05%± of
levocetirizine dihydrochloride) within 15 minutes.
Keywords: Melt-in-mouth tablet, montelukast, levocetirizine, croscarmellose sodium, crospovidone, sodium starch
glycolate, and Kyron T 314.
INTRODUCTION
Melt-in-mouth tablets are one of the new types of tablet
formulations which combine the advantage of liquid and
solid dosage forms. This type of dosage form is especially
suitable for those who are unable to take conventional oral
formulations1.Now-a-days, the concept of melt-in-mouth
tablets has been emerged as a good means to improve patient
comfort. These tablets are broken down quickly and dissolve
the medicaments as they interact with salivary secretions,
avoiding the use of water. Because of this advantage, such
tablets are suitable for children and elderly patients as they
face difficulty in administering conventional tablets. Elderly
patients need to administer drugs regularly to lead their
healthy life. Children are finding difficulty in swallowing
tablets since they have undeveloped muscular and nervous
systems. The swallowing problems are also common in cases
such as patients with motion sickness, sudden episodes of
allergic attack or coughing and due to lack of water. These
problems can be avoided by preparing melt-in-mouth tablets2.
* For Correspondence:
E-mail: nagesh_73@rediffmail.com
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This type of tablet is also named as mouth dissolving tablets,
reprimelts, porous tablets, oro-dispersible, fast dissolving or
rapidly disintegrating tablets3. Some medicaments enter to the
blood stream through the oral cavity, pharynx and esophagus
as saliva carried down to the GIT. In such instances, the bioavailability of medicaments is more than that of tablets4. The
criteria considered for selection of the drug are it should
have relatively low dose and bitter less in taste.
For the present investigation, montelukast sodium and
levocetirizine dihydrochloride were selected as model drugs,
as the properties of these drugs are meeting the criteria for
mouth dissolving tablets. Montelukast sodium is a leukotriene
receptor antagonist that acts by preventing the effects
of cysteinyl leukotrienes. It is used in the prevention and
management of asthma. Levocetirizine dihydrochloride is a
long acting peripheralH1receptor antagonist. Allergic rhinitis
is a disorder of the nose caused by inflammation mediated
by immunoglobulin E (IGE) that lines the membranes of
the nose after allergen exposure. It will prevent the release
of other allergy chemicals and increase blood supply to the
areas5, 6.Combination of montelukast with levocetirizine
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provides additional benefits in comparison with each agent
and could be considered for patients whose quality of life is
impaired by persistent asthma and allergic rhinitis7.
In the present investigation an attempt was made to develop
a simple, precise, accurate and reproducible method for
simultaneous estimation of montelukast sodium and
levocetirizine dihydrochloride in the formulation which is
a basic parameter to quantify the amount of drugs present
in a combination. Attempts were also made to design and
characterize oro-dispersible tablet of montelukast sodium
and levocetirizine dihydrochloride to achieve increased
dissolution rate, hence the patient’s compliance and also to
develop means of administration to patients who are unable
to swallow ordinary tablets and in case of motion sickness.
The main idea behind the fabrication of such dosage form
is the use of different super disintegrants viz. croscarmellose
sodium, crospovidone, sodium starch glycolate and kyron
T314, which burst the tablets immediately after placing
over tongue, and release the medicaments in saliva. In the
formulation, aspartame and mannitol were also included as
sweetener. These systems may provide better qualities with
enhanced drug bio-availability.
MATERIALS AND METHOD
Materials
Montelukast sodium and levocetirizine dihydrochloride were
obtained from Morpen Lab, Solan (India) and Micro Labs
Ltd. (Bangalore). Croscarmellose sodium, crospovidone
sodium starch glycolate and kyron T 314 were obtained as
gift samples from Wallace Pharma, Goa. Microcrystalline
cellulose and mannitol were obtained from S.D Fine
Chemical, Mumbai, India. All chemicals and reagents were
obtained as AR grade.
Methods
I. Preformulation studies:
Preformulation studies such as melting point, IR spectral
analysis, compatibility studies and λmax determination were
conducted by appropriate methods to check the identity and
purity of the samples.

CX =

(A 1∗y2) − (A 2∗y1)

CY =

(A 2∗x1) − (A 1∗x2)

x1y2 −x2y1

x1y2 −x2y1

Where,
A1 and A2 are absorbance of sample solution at 245 and 231
nm respectively.
x1= Absorptivity of montelukast sodium at 245 nm
x2 = Absorptivity of montelukast sodium at 231 nm
y1 = Absorptivity of levocetirizine dihydrochloride at 245
nm
y2= Absorptivity of levocetirizine dihydrochloride at 231nm
Cx and Cy are concentration of montelukast sodium and
levocetirizine dihydrochloride in sample solution8.
III. Pre-compressional evaluations:
Angle of repose:
The method used was fixed funnel technique. The powdered
blend was allowed to pass using a cut funnel till the highest
pile height (h) was reached. Radius of base of pile (r) was
measured and the angle of repose was calculated using the
formula:
θ = tan-1 h/r
Where, θ= angle of repose, h =length of pile and r =radius
of the base of the pile9.
Bulk density:
Bulk density apparatus was used to measure bulk density
(ρb). The volume (Vb) occupied by a given weight of powder
(M) was noted. The bulk density was calculated by using the
formula9:
ρb = M/Vb
Tapped density:
The powder mix was taken in a measuring cylinder and
tapped for a specified period of time. The true volume (Vt)
and weight (M) of the powder was noted down. The tapped
density (ρt) was determined by using the formula9:
ρt = M/Vt

II. Analytical Method:

Carr’s consolidation index:

The method involves the measurement of absorptivity at
its λmax. Two wavelengths selected for the development of
simultaneous equation were 245 nm (λ1) and 231nm (λ2).
Absorptivity of both the drugs at both the wavelengths were
determined and the equations obtained for the estimation of
concentration were

Carr’s consolidation index (CI) (%) of the powdered mix was
calculated using the formula9.
Compressibility index (CI)
=

Tapped density (ρt ) −Bulk density (ρb)
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Hausner’s ratio:

allowed to rotate for four min at 25 revolutions per minute

Hausner’s ratio is a ratio of tapped bulk density to untapped
bulk density. It was determined by using the formula9:

or to complete100 revolutions. The tablets were collected,
dedusted and noted down the weight of all tablets. The
difference in weight before and after testing was calculated

Hausner’s ratio = ρt/ρb

and percentage friability was determined using the following

Where, ρt is tapped bulk density and ρb is untapped bulk
density. The Lower Hausner’s ratio (< 1.25) indicates better
flow properties than the higher ones (>1.25).
IV. Preparation of mouth dissolving tablets using
montelukast sodium and levocetirizine dihydrochloride:
Direct compression technique was used to formulate Meltin-mouth tablets of montelukast sodium and levocetirizine
dihydrochloride. Different super disintegrants of varied
concentrations were used for developing mouth dissolving
tablets. Quantities of excipients used in different formulations
are given in Table No 1. All the adjuvants were weighed and
mixed thoroughly in mortar, finally talc and magnesium
stearate was added and the blend was compressed into
tablets using Proton eight station mini press tablet machine
(8 mm flat-faced punches). The total weight of each tablet
was 200mg.

formula9:
Friability (%) =
Water absorption ratio:

Loss in weight
Initial weight

x 100

One tablet was placed in a petri plate (internal diameter
5.5cm) that contains 6ml purified water on which a piece of
tissue paper with two folds was kept. The wetted tablet was
taken and weight was noted down. Water absorption ratio, R
was calculated by using the formula10.
R=

(Wa – Wb)
Wb

x 100

Where, Wa= weight of tablet before test and Wb= weight of
tablet after water absorption.
Wetting time:

V. Post compression parameters:

One tablet was placed in a petri plate (internal diameter

Weight variation test:

5.5cm) that contained 6ml purified water on which a piece of
tissue paper with two folds was kept. The time required to

Twenty tablets were selected randomly, weight of individual
tablet and collective weight of all tablets were noted down.
The average weight of one tablet was calculated from
collective weight and the percentage weight deviation was
calculated.

Drug content uniformity test:

Hardness test:

of buffer (pH 6.8) solution in volumetric flask. The resulting

The hardness of the tablet was checked using Monsanto and
Pfizer hardness testers9.

solution was clarified, required dilution was made and the

wet the tablet completely was noted10.

This test was performed by selecting five tablets randomly.
Accurately weighed tablet was crushed and dissolved in 100 ml

content was determined using UV -spectrophotometer at
245nm and 231nm11.

Thickness:
The thicknesses of the selected tablets were determined
using screw gauge and Vernier calipers. Four tablets were
taken and their thickness was recorded. It is expressed in
mm9.

Disintegration test:

Friability test:

assembly was placed in water bath maintained at 37 ± 20C.

Roche friabilator (Servewell Equipment Pvt. Ltd. Mumbai,
India) was used to determine the percentage friability.
Required number of tablets were selected randomly and
the collective weight of all tablets was noted down. These
tablets were charged into friabilator. The equipment was

The time in seconds required for the breaking down of

40
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This test was conducted using disintegration test apparatus
(Servewell Equipment Pvt. Ltd. Mumbai, India). One tablet
was placed in each of six tubes of the basket. The basket

tablet and the state of no trace of mass should remain in
the tubes of the basket was measured. The standard limit
for disintegration of melt-in-mouth tablet is less than three
minutes12,13.
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In-vitro dissolution test:

RESULTS

The in-vitro dissolution study of mouth dissolving tablets made
of montelukast sodium and levocetirizine dihydrochloride
was conducted using USP type – II dissolution apparatus
(Electrolab – TDT – 08L) conditions used for the test is as
follows:

In the present study melt-in-mouth tablets comprising
montelukast sodium and levocetirizine dihydrochloride were
prepared by direct compression technique using crospovidone,
croscarmellose sodium, sodium starch glycolate and kyron
T314 as super disintegrants. Altogether eight formulations
were prepared as per the Table No. 1. A suitable analytical
method was used for simultaneous estimation of
montelukast sodium and levocetirizinedihydrochloride7.
The results of pre-compression parameters such as flow
of powder, measurement of density, Hausner’s ratio and
percentage consolidation index are tabulated in Table
No.2.The results of post-compression parameters such as
weight uniformity, hardness, thickness, percentage friability,
drug content uniformity, wetting time, water absorption
ratio and disintegration time are given in Table No.3. In vitro
dissolution study was conducted for all the formulations
and the results are shown in Figure No 1-4. Based on the
results of all the formulations, F4 formulation was chosen as
a better formulation and used for stability studies, the result
is depicted in Table No.4.

Phosphate buffer solution (900 ml; pH 6.8) was used
as dissolution medium, temperature was maintained at
37±0.5oC and rotation was fixed at 50 rpm. Every interval of
time, 5 ml of aliquot was withdrawn and the same quantity
of fresh solution was replaced. The samples were filtered and
suitably diluted with pH6.8 buffer solution. The absorbance
of the solution was measured for both 245 nm and 231nm
using UV-visible spectrophotometer (Shimadzu UV -1800)14.
VI. Stability Studies:
Best formulation was chosen for stability studies as per
ICH guidelines for three months. At an interval of 30 days,
samples were taken and tested for physical appearance,
drug content, wetting studies, and disintegration test and
dissolution studies15.

Table 1: Formulation of montelukast sodium and levocetirizine dihydrochloride mouth dissolving tablets.
Ingredients
Montelukast Sodium
Levocetirizine dihydrochloride
Croscarmellose Sodium
Crospovidone
Sodium starch glycolate
Kyron T-314
MCC
Mannitol
Aspartame
Mg stearate
Talc
Total-Wt(Mg)
* Quantity in mg for one tablet

F1
10
5
3
50
122
4
3
3
200

F2
10
5
4
50
121
4
3
3
200

F3
10
5
6
50
119
4
3
3
200

F4
10
5
8
50
117
4
3
3
200

F5
10
5
6
50
119
4
3
3
200

F6
10
5
8
50
117
4
3
3
200

F7
10
5
3
50
122
4
3
3
200

F8
10
5
4
50
121
4
3
3
200

Table 2: Pre-compression parameters for all the formulations
Parameters
Formulation
code
Angle of repose (θ) Bulk density (gm/cm3) Tapped density (gm/cm3) Hausner’s ratio Compressibility index (%)
25.45±0.773
0.390±0.007
0.448±0.010
1.14±0.005
13.08±0.441
F1
25.18±0.725
0.358±0.010
0.402±0.007
1.12±0.018
11.41±0.924
F2
24.97±8047
0.395±0.001
0.456±0.024
1.15±0.002
13.32±0.005
F3
25.21±1.785
0.373±0.013
0.427±0.017
1.14±0.006
12.66±0.409
F4
25.20±0.732
0.394±0.007
0.451±0.010
1.14±0.024
12.80±1.322
F5
24.23±0.372
0.385±0.014
0.450±0.025
1.13±0.011
13.78±1.636
F6
24.27±0.814
0.390±0.019
0.443±0.018
1.13±0.018
11.98±1.660
F7
24.79±1.141
0.402±0.008
0.465±0.010
1.15±0.000
13.55±0.226
F8
Note: The values presented are ± SD’s of three determination
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Table 3: Post-compression parameters for all formulations.
Parameters
Formulation
Code

Weight
variation
(mg)

Thickness
(mm)

F1

197±0.19

F2

Hardness
(kg/cm2)

Friability
(%)

3.15±0.01

3.26±0.19

196±0.50

3.04±0.01

F3

199±0.66

F4

Drug content uniformity (%)

Wetting time
(Sec)

Water
absorption
ratio (%)

In vitro
disintegration
test (Sec)

Montelukast
Sodium

Levocetirizine
dihydrochloride

0.20

96.28±0.37

96.96±0.60

43.10±0.33

62.45±0.19

49.66±2.14

3.33±0.19

0.20

96.28±0.37

90.97±1.37

39.33±0.19

66.81±0.10

40.33±0.50

3.30±0.03

3.26±0.19

0.30

96.28±0.37

95.14±0.40

34.00±0.33

60.26±0.28

28.33±0.50

196±0.50

3.38±0.05

3.46±0.38

0.40

96.28±0.37

96.96±0.60

29.33±0.38

64.16±0.05

19.33±0.69

F5

198±0.33

3.21±0.08

2.90±0.33

0.29

95.18±0.24

95.14±0.40

36.00±0.33

62.70±0.23

50.00±0.88

F6

199±0.19

3.40±0.03

3.03±0.19

0.30

96.28±0.37

95.14±0.40

33.00±0.33

68.17±0.09

42.33±0.83

F7

199±0.19

3.43±0.05

3.26±0.19

0.40

95.18±0.24

95.14±0.40

41.33±0.76

60.57±0.32

42.66±1.71

F8

199±0.19

3.19±0.01

3.03±0.19

0.20

96.28±0.37

96.96±1.37

37.00±0.66

64.24±0.39

38.00±1.20

Note: The values presented are ± SD’s of three determination.
Table 4: Stability parameters of best formulation containing crospovidone as super disintegrants (F4)
Parameters
Formulation (F8 )

After one month
Montelukast Levocetirizine
sodium
Dihydrochloride

Physical appearance
Drug content (%)

After two month
Montelukast
sodium

No change
96.11

Levocetirizine
Dihydrochloride

After three month
Montelukast
sodium

No change

96.32

95.77

Levocetirizine
dihydrochloride

No change
95.82

95.09

95.11

Wetting time (Sec)

29.33

30.12

29.88

In-vitro Disintegration
time(Sec)

19.33

18.03

20.67

% CDR at 15 Min.

95.76

91.07

Figure 1: Comparative in vitro release profile of levocetirizine
dihydrochloride (formulation F1–F4) in phosphate buffer (pH 6.8)
42
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95.12

90.69

94.89

90.12

Figure 2: Comparative in vitro release profile of levocetirizine
dihydrochloride (formulation F5–F8) in phosphate buffer (pH 6.8)
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Figure 3: Comparative in vitro release profile of montelukast
sodium (formulation F1 – F4) in phosphate buffer (pH 6.8)

Figure 4: Comparative in vitro release profile of montelukast
sodium (formulation F5 – F8) in phosphate buffer (pH 6.8)

DISCUSSION
Based on the results of IR and melting point studies (results
not shown), it was confirmed that the obtained drug samples
meet the requirements for purity. The compatibility study
results confirm that there was no interaction between
drugs and excipients (results not shown). From the results
of pre-formulation parameters, it was observed that all the
formulations were within the standard limits and indicated
that the powder mix of all the formulations showed free
flowing property (Table No 2).
The hardness of all the formulations was within the
appropriate ranges indicating that the tablets have sufficient
strength with an ability to withstand various types of shocks.
This was supported by low percentage friability values of
the formulations (< 1%). The result of weight variation test
indicates that the weight of all the batches of tablets was
found to be uniform with least percentage weight variation

and within the standard range. The percentage drug content
values of all the batches were found to be uniform and also
observed within the standard range. The result of these two
parameters explains the uniform mixing of drugs and nondrug components. The wetting time and water absorption
ratio data have shown that the tablets were wetted at faster
rate which helps in faster disintegration of tablets. The time
required to disintegrate such type of tablets was found to
be within the limits and meets the requirements for melt-inmouth tablets. It was also observed that the tablets prepared
using crospovidone as a super-disintegrating agent bursts
rapidly due to high swelling capacity when compared to
formulations containing other super-disintegrating agents.
Among all the formulation, F4 containing crospovidone(8%)
was found to be better formulation, since these tablets have
shown better mechanical strength, least percentage friability
and less wetting time (29.33±0.38 sec.) and disintegration
time(19.33±0.69sec.), which is an ideal requirement for meltin-mouth tablets. The result of dissolution study indicated
that percentage CDR from F4 formulation was found to be
96.06±%0.80 and 91.69±%1.05 for montelukast sodium and
levocetirizine dihydrochloride(Figure No 1-4)respectively
at the end of 15 min; whereas the drug release from other
formulations was found to be less. The good drug release
from F4 tablet may be due to sudden dissolution fluid
uptake into the tablet that leads to swelling of tablets which
results in bursting of tablets. These disaggregated particles
dissolve quickly in the dissolution medium thereby increase
the dissolution rate of the drugs. The results of stability
study (data not presented) showed that there was no much
variation in the physical appearance, drug content, wetting
time and in- vitro drug release studies.
CONCLUSION
Melt-in-mouth tablets prepared of montelukast sodium
in combination with levocetirizine dihydrochloride were
successfully prepared by direct compression technique
using different super-disintegrants. The ability of superdisintegrants to disintegrate tablets is in the following order:
crospovidone>croscarmellose sodium > sodium starch
glycolate> Kyron T314.From the study it was observed that
crospovidone at a concentration of 8% w/w (F4) showed
maximum in-vitro drug release, and hence this formulation
emerged as the best formulation
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